Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Mercati
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Tape desk, TradeNews BD (2026-10-02): Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. Fonte primaria: originale su CNBC Top News (cnbc.com).